Wednesday | 3 December, 2008
Alchemia banks on 2010
Alchemia registers loss, expects to be in profit in 2010
Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.
Equity increased from around $87 million to $102 million.
The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
“Just Graphics” isn’t enough any more 2008-11-28 15:02:00+11
Capture and Digitize Your Treasure Moments ~ Compro VideoMate C200 USB A/V Capture Stick 2008-11-26 12:37:00+11
AOC's Widescreen 22" LCD Monitor with All-Aluminum Chassis: Zifas 2218Ph - Flexible flair for discerning users 2008-11-24 13:30:00+11
Kingston Technology Launches HyperX T1 Series Memory 2008-11-19 11:00:00+11
Erase your discs with Lite-On SmartErase 2008-11-12 14:00:00+11
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector.
